DCTH Share Price Performance
US$10.91
-5.28 (-32.61%)
48.9% undervalued intrinsic discount
US$21.33
Fair Value
Price US$10.91
AnalystConsensusTarget US$21.33
AnalystLowTarget US$18.00
AnalystHighTarget US$30.83
Fair ValueUS$21.33
Share Pricen/a
Delcath Systems, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 36 Fair Values set on narratives written by author
DCTH Community Narratives
AN
Fair Value
·Fair Value US$21.33 48.9% undervalued intrinsic discount
Expanded Clinical Trials And Program Integration Will Define Oncology's Future
1users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
AN
Fair Value
·Fair Value US$18 39.4% undervalued intrinsic discount
Operational Hurdles Will Stunt Clinical Expansion Despite Emerging Promise
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value US$30.83 64.6% undervalued intrinsic discount
HEPZATO Kit Use And Emerging Markets Will Widen Oncology Reach
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Expanded Clinical Trials And Program Integration Will Define Oncology's Future
Key Takeaways Growing demand for liver-focused cancer treatments and broader clinical trials are expanding Delcath's addressable markets and supporting long-term revenue growth. Increased market access, hospital adoption, and European expansion are driving sustained volume growth and profitability despite some downward pricing pressure.Read more
AN
US$21.33
48.9% undervalued intrinsic discount
Fair Value
Revenue
24.61% p.a.
Profit Margin
2.85%
Future PE
193.48x
Price in 2029
US$26.33
Operational Hurdles Will Stunt Clinical Expansion Despite Emerging Promise
Key Takeaways Difficulties activating new clinical sites and workflow complexities may restrict sales growth and operational leverage, despite favorable long-term oncology market trends. Margin pressures from discounted pricing and increased R&D spending could outpace revenue growth, risking stagnation even as geographic and portfolio expansion efforts continue.Read more
AN
US$18
39.4% undervalued intrinsic discount
Fair Value
Revenue
18.64% p.a.
Profit Margin
13.08%
Future PE
41.02x
Price in 2029
US$22.14
HEPZATO Kit Use And Emerging Markets Will Widen Oncology Reach
Key Takeaways Rapid expansion of treatment centers and improved access programs are expected to drive substantial revenue growth and greater institutional adoption. Leadership in targeted cancer therapies and self-funded innovation positions the company for sustainable margin gains and enlarged market share globally.Read more
AN
US$30.83
64.6% undervalued intrinsic discount
Fair Value
Revenue
50.01% p.a.
Profit Margin
40.37%
Future PE
16.76x
Price in 2028
US$35.01
Trending Discussion
Recently Updated Narratives
AN
DCTH: 2026 Spend Increase Will Drive Hepatic Cancer Therapy Adoption
Fair Value: US$21.33 48.9% undervalued intrinsic discount
17 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
DCTH: Higher 2026 Spending Will Support Liver Cancer Therapy Expansion
Fair Value: US$18 39.4% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
HEPZATO Kit Use And Emerging Markets Will Widen Oncology Reach
Fair Value: US$30.83 64.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Delcath Systems, Inc. Key Details
About DCTH
- Founded
- 1988
- Employees
- 156
- CEO
- WebsiteView website
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
